# Instil Bio

Source: https://onco.cc/companies/instil-bio/  
OnCo record `instil-bio` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Instil Bio is a listed biotechnology company that previously developed immune cell therapies and then a two-target antibody for solid tumours. It stopped that antibody programme in January 2026 and now seeks new medicines to acquire or license.

## Summary

Instil Bio, Inc. is headquartered in Dallas, Texas, was incorporated in Delaware in August 2018 and began operations in 2019; its shares trade on Nasdaq as TIL. It previously developed tumour-infiltrating lymphocyte cell therapies, including a folate receptor alpha CoStAR TIL programme (ITIL-168 and ITIL-306), which it discontinued. In August 2024 its wholly owned subsidiary Axion Bio, Inc. in-licensed AXN-2510, a PD-L1 and VEGF bispecific antibody, from ImmuneOnco Biopharmaceuticals (Shanghai); the phase 1 trial NCT07159828 in advanced solid tumours was terminated, and the licence ended in January 2026. Its stated strategy is to pursue acquisitions or in-licensing of therapeutic candidates. Its first cancer trial registered under the sponsor name Axion Bio, Inc, NCT07159828, was posted on ClinicalTrials.gov in September 2025.

## Fields

- Kind: Company
- Last checked: 2026-10-29
- Also known as: Axion Bio
- HQ: Dallas, TX
- Type: biotech
- Website: https://instilbio.com/
- Ticker: TIL

## Notes

- Facts come from the Form 10-K filed on 27 March 2026, read on 29 October 2026; the company website gives little detail and the investor site refused an automated fetch.
- The reason for discontinuing AXN-2510 is not stated in the part of the filing read.
- Instil Bio's own TIL trials predate 2024; only the Axion Bio sponsor name first appears on the registry in 2025.

## Sources

- Official website: https://instilbio.com/
- Instil Bio Form 10-K for 2025 (SEC): https://www.sec.gov/Archives/edgar/data/1789769/000178976926000019/til-20251231.htm
- ClinicalTrials.gov: phase 1 trial of AXN-2510 (NCT07159828): https://clinicaltrials.gov/study/NCT07159828

## Connected records

- fronts: [Cell Therapy](https://onco.cc/fronts/cell-therapy/), [Immunotherapy](https://onco.cc/fronts/immunotherapy/)
- technologies: [Bispecific antibodies](https://onco.cc/technologies/bispecific-antibody/), [TIL therapy](https://onco.cc/technologies/til-therapy/)
- targets: [PD-L1](https://onco.cc/targets/pdl1/), [VEGF / VEGFR](https://onco.cc/targets/vegf/)

---
JSON: https://onco.cc/api/v1/entities/instil-bio.json